Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Follow–Up Data Completed to Evaluate Safety and Effectiveness of Resten–MP in the Reduction of In–Stent Cardiovascular Restenosis BLOOMINGTON, Ind. (July 9, 2007) — Cook Medical announced completion of target patient enrollment and six–month follow–up data in phase II of the APPRAISAL clinical
Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company September 10, 2008. Harvard Club NYC 07.30 — 10.30 a.m. Dr. Leslie Hudson, President and CEO, AVI BioPharma RNA–based drug discovery and development Professor Francesco Muntoni, Professor of
Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company September 10, 2008 Dr. Leslie Hudson, President and CEO, AVI BioPharma RNA–based drug discovery and development Audio (MP3) , Slides (PDF) Professor Francesco Muntoni, Professor of Pediatric
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Sarepta does not undertake any obligation to update forward-looking statements after the date of such releases expect to the extent required under applicable federal and state securities laws.”
This website contains links to websites maintained by other companies. Sarepta is providing these links to readers only as a convenience. The inclusion of any link does not imply that Sarepta endorses any third-party website or third-party company or product. Sarepta does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.